title: Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment.
authors.forename: Liang
authors.initials: L
authors.lastname: Zhang
authors.forename: Kate J
authors.initials: KJ
authors.lastname: Newberry
authors.forename: Michael
authors.initials: M
authors.lastname: Wang
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000818:Animals; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000201:enzymology; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D010880:Piperidines; D011173:Portraits as Topic; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D011720:Pyrazoles / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D009363:Neoplasm Proteins; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000225:Adenine